Emergent BioSolutions与SAB Biotherapeutics, Inc.正式签署长期战略生产合作协议,双方将携手推进针对1型糖尿病的候选药物SAB-142的研发进程。这项合作标志着两家生物技术企业在糖尿病治疗领域迈出重要一步,通过整合双方在生物制药生产与技术研发方面的专业优势,为SAB-142的临床开发与未来商业化生产提供坚实保障。
Emergent BioSolutions与SAB Biotherapeutics, Inc.正式签署长期战略生产合作协议,双方将携手推进针对1型糖尿病的候选药物SAB-142的研发进程。这项合作标志着两家生物技术企业在糖尿病治疗领域迈出重要一步,通过整合双方在生物制药生产与技术研发方面的专业优势,为SAB-142的临床开发与未来商业化生产提供坚实保障。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.